Эффективность и безопасность применения пимекролимуса в лечении атопического дерматита у детей

Атопический дерматит (АтД) — одно из наиболее распространенных воспалительных заболеваний кожи. Раннее лечение АтД необходимо для предотвращения развития заболеваний атопической природы, таких как астма, аллергический ринит и др. Топические глюкокортикоиды (ТГК) используются в качестве терапии первой линии, но их длительное применение представляет риск для здоровья пациента. Несмотря на быстрый клинический ответ при обострении кожного процесса, длительное применение ТГК в первой линии терапии сопровождается рядом нежелательных явлений, включающих атрофию кожи, подавление гипоталамо-гипофизарно-надпочечниковой оси, телеангиэктазии и др. Все это ограничивает долгосрочное применение ТГК, особенно при лечении пациентов детского возраста и использовании препарата в чувствительных зонах, таких как лицо и интертригинозные области. Из-за этих ограничений ТГК следует использовать только в течение короткого промежутка времени. Ограничения как по продолжительности лечения, так и по количеству применяемых препаратов делают ТГК неоптимальными для длительного лечения АтД. Пимекролимус (1% крем) является местным ингибитором кальциневрина, который показан для лечения АтД легкой и умеренной степени тяжести. Пимекролимус не вызывает выраженных побочных эффектов по сравнению с ТГК и хорошо переносится при длительном применении.

1. Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345–360. doi: https://doi.org/10.1016/s0140-6736(20)31286-1

2. Weidinger S, Beck LA, Bieber T, et al. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1. doi: https://doi.org/10.1038/s41572-018-0001-z

3. Raimondo A, Lembo S. Atopic Dermatitis: Epidemiology and Clinical Phenotypes. Dermatol Pract Concept. 2021;11(4): e2021146. doi: https://doi.org/10.5826/dpc.1104a146

4. Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol. 2012;26(8):1045–1060. doi: https://doi.org/10.1111/j.1468-3083.2012.04635.x

5. Watson W, Kapur S. Atopic dermatitis. Allergy Asthma Clin Immunol. 2011;7(Suppl 1):S4. doi: https://doi.org/10.1186/1710-1492-7-S1-S4

6. Barnetson RS, Rogers M. Childhood atopic eczema. BMJ. 2002;324:1376–1379. doi: https://doi.org/10.1136/bmj.324.7350.1376

7. Bieber T. Atopic dermatitis. N Engl J Med. 2008;358(14): 1483–1494. doi: https://doi.org/10.1056/NEJMra074081

8. Paller A, Spergel J, Mina-Osorio P, Irvine A. The atopic march and atopic multimorbidity: Many trajectories, many pathways. J Allergy Clin Immunol. 2019;143(1):46–55. doi: https://doi.org/10.1016/j.jaci.2018.11.006

9. Elias PM, Hatano Y, Williams ML. Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol. 2008;121(6):1337–1343. doi: https://doi.org/10.1016/j.jaci.2008.01.022

10. Lee HJ, Lee SH. Epidermal permeability barrier defects and barrier repair therapy in atopic dermatitis. Allergy Asthma Immunol Res. 2014;6(4):276–87. doi: https://doi.org/10.4168/aair.2014.6.4.276

11. Boguniewicz M, Leung DY. Recent insights into atopic dermatitis and implications for management of infectious complications. J Allergy Clin Immunol. 2010;125(1):4–13. doi: https://doi.org/10.1016/j.jaci.2009.11.027

12. Tang TS, Bieber T, Williams HC. Are the concepts of induction of remission and treatment of subclinical inflammation in atopic dermatitis clinically useful? J Allergy Clin Immunol. 2014;133(6):1615–1625.e1. doi: https://doi.org/10.1016/j.jaci.2013.12.1079

13. Hepburn D, Yohn JJ, Weston WI. Topical steroid treatment in infants, children, and adolescents. Adv Dermatol. 1994;9:225–255; discussion 255.

14. Raimer SS. Managing pediatric atopic dermatitis. Clin Pediatr (Phila). 2000;39(1):1–14. doi: https://doi.org/10.1177/000992280003900101

15. Sulzberger MB, Witten VH. The effect of topically applied compound F in selected dermatoses. J Investig Dermatol. 1952;19(2):101–102. doi: https://doi.org/10.1038/jid.1952.72

16. Marshall HF, Leung DYM, Lack G, et al. Topical steroid withdrawal and atopic dermatitis. Ann Allergy Asthma Immunol. 2023;132(4):423–425. doi: https://doi.org/10.1016/j.anai.2023.12.022

17. Maghen P, Unrue EL, Oussedik E, et al. Regardless of how risks are framed, patients seem hesitant to use topical steroids for atopic dermatitis. Br J Dermatol. 2019;181(4):842–844. doi: https://doi.org/10.1111/bjd.17929

18. Gutfreund K, Bienias W, Szewczyk A, Kaszuba A. Topical calcineurin inhibitors in dermatology. Part I: Properties, method and effectiveness of drug use. Postep Dermatol Alergol. 2013;30(3): 165–169. doi: https://doi.org/10.5114/pdia.2013.35619

19. Luger T, Augustin M, Lambert J, et al. Unmet medical needs in the treatment of atopic dermatitis in infants: an expert consensus on safety and efficacy of Pimecrolimus. Pediatr Allergy Immunol. 2021;32(3):414–424. doi: https://doi.org/10.1111/pai.13422

20. Hanna S, Zip C, Shear NH. What is the risk of harm associated with topical calcineurin inhibitors? J Cutan Med Surg. 2019;23(4_suppl):19S–26S. doi: https://doi.org/10.1177/1203475419857688

21. Shin N, Jung N, Lee SE, et al. Pimecrolimus interferes the therapeutic efficacy of human mesenchymal stem cells in atopic dermatitis by regulating NFAT-COX2 signaling. Stem Cell Res Ther. 2021;12(1):482. doi: https://doi.org/10.1186/s13287-021-02547-8

22. Sigurgeirsson B, Boznanski A, Todd G, et al. Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial. Pediatrics. 2015;135(4):597–606. doi: https://doi.org/10.1542/peds.2014-1990

23. Luger T, De Raeve L, Gelmetti C, et al. Recommendations for pimecrolimus 1% cream in the treatment of mild-to-moderate atopic dermatitis: from medical needs to a new treatment algorithm. Eur J Dermatol. 2013;23(6):758–766. doi: https://doi.org/10.1684/ejd.2013.2169

24. Nuutinen P, Riekki R, Parikka M, et al. Modulation of collagen synthesis and mRNA by continuous and intermittent use of topical hydrocortisone in human skin. Br J Dermatol. 2003;148(1):39–45. doi: https://doi.org/10.1046/j.1365-2133.2003.05018.x

25. Grassberger M, Steinhoff M, Schneider D, Luger TA. Pimecrolimus — an anti-inflammatory drug targeting the skin. Exp Dermatol. 2004;13(12):721–730. doi: https://doi.org/10.1111/j.0906-6705.2004.00269.x

26. Kyllönen H, Remitz A, Mandelin JM, et al. Effect of 1-year intermittent treatment with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis. Br J Dermatol. 2004;150(6):1174–1181. doi: https://doi.org/10.1111/j.1365-2133.2004.06017.x

27. Sigurgeirsson B, Ho V, Ferrandiz C, et al. Effectiveness and safety of a prevention-of-flare-progression strategy with pimecrolimus cream 1% in the management of paediatric atopic dermatitis. J Eur Acad Dermatol Venereol. 2008;22(11):1290–1301. doi: https://doi.org/10.1111/j.1468-3083.2008.02785.x

28. Gollnick H, Kaufmann R, Stough D, et al. Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial. Br J Dermatol. 2008;158(5):1083–1093. doi: https://doi.org/10.1111/j.1365-2133.2008.08484.x

29. Ruer-Mulard M, Aberer W, Gunstone A, et al. Twice-daily versus once-daily applications of pimecrolimus cream 1% for the prevention of disease relapse in pediatric patients with atopic dermatitis. Pediatr Dermatol. 2009;26(5):551–558. doi: https://doi.org/10.1111/j.1525-1470.2009.00981.x

30. Kapp A, Papp K, Bingham A, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol. 2002;110(2): 277–284. doi: https://doi.org/10.1067/mai.2002.126500

31. Lübbe J. Secondary infections in patients with atopic dermatitis. Am J Clin Dermatol. 2003;4(9):641–654. doi: https://doi.org/10.2165/00128071-200304090-00006

32. Leung DY. Infection in atopic dermatitis. Curr Opin Pediatr. 2003;15(4):399–404. doi: https://doi.org/10.1097/00008480-200308000-00008

33. Kong HH, Oh J, Deming C, et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 2012;22(5):850–859. doi: https://doi.org/10.1101/gr.131029.111

34. Luger TA, Lahfa M, Fölster-Holst R, et al. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J Dermatolog Treat. 2004;15(3):169–178. doi: https://doi.org/10.1080/09546630410033781

35. Lübbe J, Friedlander SF, Cribier B, et al. Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice. Am J Clin Dermatol. 2006;7(2):121–131. doi: https://doi.org/10.2165/00128071-200607020-00005

36. Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics. 2002;110(1 Pt 1):e2. doi: https://doi.org/10.1542/peds.110.1.e2

37. Draelos ZD. Use of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis in thin and sensitive skin areas. Curr Med Res Opin. 2008;24(4):985–994. doi: https://doi.org/10.1185/030079908X280419

38. Hengge UR, Ruzicka T, Schwartz RA, et al. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54(1):1–15. doi: https://doi.org/10.1016/j.jaad.2005.01.010

39. Plotz SG, Ring J. What’s new in atopic eczema? Expert Opin Emerg Drugs. 2010;15(2):249–267. doi: https://doi.org/10.1517/14728211003792518

40. Sonkoly E, Muller A, Lauerma AI, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol. 2006;117(2):411–417. doi: https://doi.org/10.1016/j.jaci.2005.10.033

41. Lewis-Jones S. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int J Clin Pract. 2006;60(8):984–992. doi: https://doi.org/10.1111/j.1742-1241.2006.01047.x

42. Matterne U, Böhmer MM, Weisshaar E, et al. Oral H1 antihistamines as ‚add-on‘ therapy to topical treatment for eczema. Cochrane Database Syst Rev. 2019;1(1):CD012167. doi: https://doi.org/10.1002/14651858.CD012167.pub2

43. Whalley D, Huels J, McKenna SP, van Assche D. The benefit of pimecrolimus (Elidel, SDZ ASM 981) on quality of life in the treatment of paediatric atopic dermatitis. Pediatrics. 2002;110(6): 1133–1136. doi: https://doi.org/10.1542/peds.110.6.1133